Cargando…
Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature
BACKGROUND: ALK-rearrangement is observed in < 5% non-small cell lung cancer (NSCLC) cases and prior to the advent of oral tyrosine kinase inhibitors, the natural history of oncogenic NSCLC was typically poor. Literature relating to regression of treatment-naïve NSCLC is limited, and regression w...
Autores principales: | Walls, Maria, Walls, Gerard M., James, Jacqueline A., Crawford, Kyle T., Abdulkhalek, Hossam, Lynch, Tom B., Peace, Aaron J., McManus, Terry E., Evans, O. Rhun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409640/ https://www.ncbi.nlm.nih.gov/pubmed/32762670 http://dx.doi.org/10.1186/s12890-020-01249-w |
Ejemplares similares
-
STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021) -
CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018) -
Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014) -
Central nervous system involvement of systemic ALK-positive histiocytosis with KIF5B-ALK fusion
por: Aoki, Yuzuna, et al.
Publicado: (2022) -
Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)